C&L: Dr. Hudson tapped to run DOV

Dr. Leslie Hudson will become DOV Pharmaceutical's CEO and president. DOV's co-founder, Dr. Arnold Lippa, currently chairman, CEO and president, will continue to serve as chairman of the board. Dr. Hudson brings over 15 years of corporate pharmaceutical experience to DOV, having served in senior level leadership positions at Pharmacia and Glaxo.

Valentis has promoted John J. Reddington, PhD, DVM, to the newly created position of COO.

Evotec has appointed Dr. Tim Tasker as executive vice president clinical development and a member of its executive committee. Most recently, Dr. Tasker was vice president global clinical units, clinical pharmacology and discovery medicine and member of the GSK Global Safety Board.

Dr. Jack Schaumberg has been appointed to the newly-created role of senior vice president of global clinical operations at PRA International. Prior to joining PRA, Dr. Schaumberg was vice president of clinical operations, Americas, for Inveresk (Charles River Laboratories).

Sirna Therapeutics has hired J. Michael French as senior vice president for corporate development. French brings to Sirna 15 years of international business experience in both the pharmaceutical and biotechnology industries, most recently as chief business officer at Entelos.

AtheroGenics has named Joseph M. Gaynor, Jr., to the newly created position of vice president and general counsel. Gaynor spent 10 years at UCB Pharma, most recently as vice president, general counsel and secretary for all US subsidiaries of the Belgian pharmaceuticals group.

The Global Alliance for TB Drug Development has named Nina Schwalbe as director of policy. Ms. Schwalbe previously directed international public health programs at the Open Society Institute.

Meir Spear, CPA from the firm of Spear & Co. CPAs, has been hired as Amazon Biotech's internal accountant.

Morgenthaler Ventures today announced that Nassim Usman, PhD, has become an entrepreneur-in-residence focusing on investment opportunities in biotechnology.

Critical Therapeutics has elected James B. Tananbaum, MD, to the company's board of directors.

Halozyme Therapeutics has named Steve Thornton to its board of directors.

Forest Laboratories announced that Phillip M. Satow has resigned from the board of directors.

James Umlah, a member of Medicure's board of directors, has resigned.

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.